ArticleEuropean radiology2021
Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.
Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 55 citations in OpenAlex.
- Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Trial
- Apparent diffusion coefficient metrics for treatment response assessment in soft tissue sarcoma: Reproducibility and prognostic value of whole-tumor and sub-regional analysis.Skeletal radiology · 2026Article
- T1 Mapping-Derived Extracellular Volume Fraction for Non-Invasive Assessment of Tumor-Stroma Ratio in Rectal Cancer.Abdominal radiology (New York) · 2026Article
- Impact of Magnetic Field Strength (1.5 T vs. 3.0 T) on the Prognostic Value of Quantitative ADC Indices in Patients After Out-of-Hospital Cardiac Arrest: A Prospective Multicenter Observational Study in Korea (The KORHN-PRO Registry).Journal of clinical medicine · 2026Article
- On-Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients.Magnetic resonance in medicine · 2026Article
- Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- ADC Histogram Features of Breast Cancer Brain Metastases as Candidate Imaging Biomarkers of Primary Tumor ER, PR, Ki-67, and Luminal Status.Diagnostics (Basel, Switzerland) · 2026Article
- Clinically aligned whole-body MRI segmentation of skeletal metastases via Supervised Anatomical Pretraining.Journal of bone oncology · 2026Article
- Multi-scanner repeatability and reproducibility of qRF-MRF breath-held and free-breathing with pilot tone in the abdomen.Magma (New York, N.Y.) · 2026Article
- Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study.Radiology. Imaging cancer · 2025Observational
- Qualitative and Quantitative Inter-Observer Agreement of Multiparametric Whole-Body MRI in Staging and Follow-Up of Myeloma Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Magnetic resonance imaging features of intrahepatic bile duct adenoma: a 10-year retrospective study.BMC medical imaging · 2025Article
- The Value of Apparent Diffusion Coefficient from Diffusion-Weighted Imaging in Differentiating Osteomyelitis and Reactive Bone Marrow Edema in Diabetic Patients.The archives of bone and joint surgery · 2025Article
- Image quality of whole-body diffusion MR images comparing deep-learning accelerated and conventional sequences.European radiology · 2024Article
- The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.Radiology · 2024Review
- Phantoms for Quantitative Body MRI: a review and discussion of the phantom value.Magma (New York, N.Y.) · 2024Review
- Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.European radiology · 2024Article
- Evaluation of deep learning reconstruction on diffusion-weighted imaging quality and apparent diffusion coefficient using an ice-water phantom.Radiological physics and technology · 2024Article
- Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.Insights into imaging · 2023Article
- Accurate, repeatable, and geometrically precise diffusion-weighted imaging on a 0.35 T magnetic resonance imaging-guided linear accelerator.Physics and imaging in radiation oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesMulticenter oncology trials increasingly include MRI examinations with apparent diffusion coefficient (ADC) quantification for lesion characterization and follow-up. However, the repeatability and reproducibility (R&R) limits above which a true change in ADC can be considered relevant are poorly defined. This study assessed these limits in a standardized whole-body (WB)-MRI protocol.
methodsA prospective, multicenter study was performed at three centers equipped with the same 3.0-T scanners to test a WB-MRI protocol including diffusion-weighted imaging (DWI). Eight healthy volunteers per center were enrolled to undergo test and retest examinations in the same center and a third examination in another center. ADC variability was assessed in multiple organs by two readers using two-way mixed ANOVA, Bland-Altman plots, coefficient of variation (CoV), and the upper limit of the 95% CI on repeatability (RC) and reproducibility (RDC) coefficients.
resultsCoV of ADC was not influenced by other factors (center, reader) than the organ. Based on the upper limit of the 95% CI on RC and RDC (from both readers), a change in ADC in an individual patient must be superior to 12% (cerebrum white matter), 16% (paraspinal muscle), 22% (renal cortex), 26% (central and peripheral zones of the prostate), 29% (renal medulla), 35% (liver), 45% (spleen), 50% (posterior iliac crest), 66% (L5 vertebra), 68% (femur), and 94% (acetabulum) to be significant.
conclusionsThis study proposes R&R limits above which ADC changes can be considered as a reliable quantitative endpoint to assess disease or treatment-related changes in the tissue microstructure in the setting of multicenter WB-MRI trials. KEY POINTS: • The present study showed the range of R&R of ADC in WB-MRI that may be achieved in a multicenter framework when a standardized protocol is deployed. • R&R was not influenced by the site of acquisition of DW images. • Clinically significant changes in ADC measured in a multicenter WB-MRI protocol performed with the same type of MRI scanner must be superior to 12% (cerebrum white matter), 16% (paraspinal muscle), 22% (renal cortex), 26% (central zone and peripheral zone of prostate), 29% (renal medulla), 35% (liver), 45% (spleen), 50% (posterior iliac crest), 66% (L5 vertebra), 68% (femur), and 94% (acetabulum) to be detected with a 95% confidence level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.